HOME >> BIOLOGY >> NEWS
Nexavar significantly extends overall survival by 44 percent in liver cancer patients

Chicago, IL June 4, 2007 -- Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that Nexavar (sorafenib) tablets significantly extended overall survival in patients with hepatocellular carcinoma (HCC), or primary liver cancer versus those taking placebo by 44% (HR=0.69; p-value=0.0006). Results were presented at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO).

The international, Phase 3, placebo-controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) Trial randomized and evaluated 602 liver cancer patients who had no prior systemic therapy at sites in the Americas, Europe, and Australia/New Zealand. The primary objective of the study was to compare overall survival in patients administered Nexavar versus those administered placebo. Median overall survival was 10.7 months in Nexavar-treated patients compared to 7.9 months in those taking placebo.

Because there are no therapies that significantly improve survival for the thousands of patients with liver cancer, these findings demonstrate the compelling study results of Nexavar as the new reference standard of care for the first-line treatment of HCC, said Dr. Josep M. Llovet, co-principal investigator and Professor of Research, Barcelona Clinic Liver Cancer (BCLC) Group, IDIBAPS, Liver Unit, Hospital Clinic Barcelona; Director of Research, HCC Program, Associate Professor of Medicine, Mount Sinai School of Medicine, New York.

Bayer and Onyx halted the SHARP trial in February 2007 when an independent data monitoring committee determined in a pre-scheduled analysis that the overall survival endpoint had been met. There were no significant differences in serious adverse event rates between the Nexavar and placebo-treated groups, with the most commonly observed serious adverse events in patients receiving Nexavar being diarrhea and hand-foot-skin reaction. Based on the strength of the d
'"/>

Contact: Charlotte Rocker
crocker@gcigroup.com
212-537-8290
GCI Group
4-Jun-2007


Page: 1 2 3

Related biology news :

1. Adding folic acid to flour significantly reduces congenital malformations
2. Antibody linked to MS significantly higher in spinal fluid of blacks
3. Herceptin plus chemotherapy significantly increases disease-free survival in breast cancer
4. High HPV concentrations combined with smoking significantly raise risks of cervical cancer
5. Using an activated-carbon filtering pitcher significantly reduces chemicals in tap water
6. Miscarriage significantly associated with increasing paternal age
7. Regular multivitamin use near time of conception significantly reduces preeclampsia risk
8. Children born after abortion ban had significantly better educational achievements
9. Brain changes significantly after age 18, says Dartmouth research
10. New data demonstrate that Benicar and Benicar HCT significantly reduces systolic hypertension
11. Elevated inflammatory enzyme, Lp-PLA2, significantly linked to ischemic stroke

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/8/2019)... (PRWEB) , ... May 08, 2019 , ... ... announced today that business professional Carol S. Mann has agreed to serve as ... as President and Chief Operating Officer, effective immediately. They will join Chairman and ...
(Date:5/8/2019)... ... May 08, 2019 , ... ... diameter of 200 microns and a lead-in fiber of 100 microns. With dimensions ... standard and positioning itself as the world leader in the development of fiber ...
(Date:5/2/2019)... PHILADELPHIA (PRWEB) , ... April 30, 2019 , ... ... & Nadel LLP is pleased to announce that Gunes Bender, Ph.D., a ... firm’s life sciences practice group. In his new role, Bender provides technical support ...
Breaking Biology News(10 mins):
(Date:4/8/2019)... , ... April 08, 2019 , ... ... communications and collaboration solutions, announced today the launch of their app integration solution, ... range of business and contact-orientated applications while using CT Cloud Voice and Skype ...
(Date:4/4/2019)... ... April 02, 2019 , ... Biomeme, Inc. , a ... latest field-ready solution for performing PCR, RT-PCR, qPCR, and Isothermal tests called ... Rosland Franklin, an English chemist and X-ray crystallographer who made significant contributions to ...
(Date:3/27/2019)... ... 26, 2019 , ... A leader in the field of Regenerative Veterinary Medicine, ... United States and Canada since 2004. The primary indications for VetStem Regenerative Cell ... the dog, cat, and horse. Recently, VetStem teamed up with the world-renowned San ...
(Date:3/23/2019)... (PRWEB) , ... March 22, 2019 , ... ... sample collection, and analysis to a team of researchers at Nnamdi Azikiwe University ... by Dr. Nneka R. Agbokoba, PhD, of the Department of Medical Laboratory Sciences ...
Breaking Biology Technology:
Cached News: